LLY Eli Lilly and Company Common St

77.99
+1.01  (1%)
Previous Close 76.98
Open 77.19
Price To book 5.80
Market Cap 82.38B
Shares 1,056,300,000
Volume 5,884,774
Short Ratio 2.41
Av. Daily Volume 3,996,910

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released May 12, 2017 - primary endpoints hit in all trials. BLA filing due 2H 2017.
Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN
Migraine prevention
Phase 3 data due 2H 2017. LLY buyout of CLCD due 1Q 2017.
Lasmiditan - SPARTAN
Migraine
Phase 3 trial to be initiated in 2017.
Ultra rapid insulin
Diabetes
Phase 3 ongoing.
Tanezumab
Chronic low back pain
Phase 3 ongoing.
Tanezumab
Cancer pain
Phase 3 ongoing.
Tanezumab
Osteoarthritis
Phase 3 initiated August 2016. Announced in January 31 earnings call that trial has been terminated - see transcript link here for details.
Solanezumab
Prodromal Alzheimer's disease
Phase 3 ongoing.
Solanezumab
Preclinical Alzheimer's disease
Phase 3 PFS data due 2017.
Ramucirumab
Second-line bladder cancer
Phase 3 initial PFS data met primary endpoint. OS data due 2018.
Ramucirumab - RAINFALL
First-line gastric cancer
Phase 3 ongoing. Data due 2017 (internal readout).
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3 initiated 1Q 2017.
Empagliflozin
Heart failure with preserved ejection fraction (HFpEF)
Phase 3 trial to be initiated in 2017.
Baricitinib
Psoriatic Arthritis
Phase 3 initiated 1Q 2017.
Empagliflozin
Heart failure with reduced ejection fraction (HFrEF)
Phase 3 data due 2019.
AZD3293
Early Alzheimer's disease
Phase 3 interim analysis April 24, 2017 met primary endpoint. Detailed data due 2H 2017 with regulatory filings due 3Q 2017.
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
Phase 3 data due late 2017.
Alimta + Keytruda (MK-3475-189/KEYNOTE-189)
First-Line Non-Squamous Non-Small Cell Lung Cancer
Phase 3 data released March 20, 2017 - PFS primary endpoint met. Regulatory filing due 2Q 2017.
Abemaciclib - MONARCH 2
Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer
Phase 2 data released June 2016. Regulatory filing due 2Q 2017.
Abemaciclib - MONARCH 1
HR+, HER2- breast cancer
Phase 3 ongoing. Data due 2017 (internal readout).
Abemaciclib - JUNIPER
Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)
Announced January 19 2016 that NDA Filing had been submitted. Three month delay announced January 13, 2017. CRL received April 14, 2017.
Baricitinib
Rheumatoid arthritis
BLA filing due 1H 2017.
Taltz
Psoriatic Arthritis